BSX-Spin-out Navilyst Charts New Course

Navilyst Medical, one of several properties recently spun out of Boston Scientific, has designs on growing into a large player in the venous access and fluid management industries.

Navilyst Medical Inc. isn’t in the business of making headlines. Company management left the front pages behind when private equity firm Avista Capital Partners acquired the venous access and fluid management businesses from constant newsmaker Boston Scientific Corp. back in February. [See Deal] Since the spin out, Navilyst executives have melded the two businesses into a single company with designs on becoming "the first choice" for venous access and fluid management devices.

Unlike Boston Scientific, Navilyst won’t be swinging for the fences with high profile acquisitions of technology-heavy, high-growth businesses like Guidant...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.